Biomarkers

Discovery and development of drugs that are both effective and safe remains a challenge in today’s healthcare industry. Translating the relevant biomarkers linked to a disease and indicative of target engagement and modulation is key to progressing beyond clinical failures. Multiple biomarker strategies require a selection of model systems that best replicate human disease. PerkinElmer offers a variety of solutions that allow scientists to more fully understand the complex role of biomarkers in the discovery, pre-clinical, and phase IV stages of drug development:

Next Gen Sequencing studies provide a discovery mechanism for mutations within disease genomes that aid in identification of biomarkers for monitoring the response of pathway targeted therapy

Imaging and quantifying tissue biomarkers in research pathology assists in understanding disease, translating to better treatment development

Monitoring and validating in vivo biomarkers during pre-clinical studies can provide previously unobtainable information such as pharmacology and side effect profiles and a drug's pharmacokinetic profile

Tools for the mechanistic studies of target compound interactions are integral in early development studies for determining pathway signaling and potential off-target effects

Our Services provide a wide range of techniques and models used to conduct biomarker discovery and analysis studies in cell based assays, animal disease models and in tissues